

SK chemicals
2024 4Q Earnings Release



We care for the future.
Healthcare, Earthcare

Disclaimer

The financial information in this document are consolidated earnings results based on K-IFRS. (Korea International Financial Reporting Standards)

The performance data for Q4 2024 included in this material has been prepared for the convenience of investors and has not yet been reviewed by an external auditor. Therefore, some of the content may change during the accounting review process.

Additionally, please note that the future outlook included in this material is based on the current business environment and the company's management strategy and may change due to future changes in the business environment and strategy adjustments.



1

Earnings Release

Company Highlight
Performance Summary

4Q24 Company Highlight

4Q24 Consolidated	Revenue 514bn KRW (+19.2% YoY, +20.6% QoQ) Operating Profit Δ29bn KRW (Turned to Loss YoY, Loss Continued QoQ)	
4Q24 Separate	Revenue 347bn KRW (+7.3% YoY, +4.4% QoQ) Operating Profit 32bn KRW (+93.4% YoY, +7.6% QoQ)	
Business Divisions	Green Chemicals	Copolyester & Monomer Expanding High-value product and Improving product portfolio
		Recycle and other business Collaboration with Automotive company in the developing CR-PET applications in electric car
	Life Science	Pharma Continuing stable sales of products
		SK bioscience Expansion of scale through the new consolidation of IDT Biologika

Performance Summary

Consolidated


Revenue 514bn KRW (+19.2% YoY, +20.6% QoQ)

Increase in sales of consolidated subsidiaries and expansion in size due to strong performance in the separate


Operating Profit $\Delta 29$ bn KRW (Turned to Loss YoY, QoQ)

Despite the increase in profit from separate, a transition to losses due to the expanded losses of consolidated subsidiaries

Revenue



Operating Profit and Margin



Separate


Revenue 347bn KRW (+7.3% YoY, $\Delta 4.4\%$ QoQ)

Expansion in size due to strong performance in the core Copolyester business


Operating Profit 32bn KRW (+93.4% YoY, +7.6% QoQ)

Increase in profit size due to strong performance in the Copolyester business

Revenue




Operating Profit and Margin



2 Performance

Performance Trends by Division
Performance by Business Unit



Performance Trends by Division

(Unit: billion KRW)

Division		2022					2023					2024				
		1Q	2Q	3Q	4Q	Total	1Q	2Q	3Q	4Q	Total	1Q	2Q	3Q	4Q	Total
Revenue	Copolyester & Monomer	202	234	207	208	851	201	212	199	198	809	222	250	229	208	910
	Functional Materials	25	23	18	16	81	23	21	18	16	77	17	18	16	16	66
	Other	3	8	4	7	21	4	4	4	5	17	5	5	4	5	20
	Pharma	77	77	80	80	314	86	86	98	106	376	86	81	84	106	357
	Total	306	342	308	310	1,266	314	323	319	325	1,280	330	354	334	335	1352
Operating Profit	Copolyester & Monomer	23	33	26	33	115	33	31	17	18	99	21	37	32	30	119
	Functional Materials	2	(1)	(1)	(2)	(2)	(0)	(1)	(0)	(1)	(2)	(0.3)	(0.6)	(0.6)	(2)	(3)
	Other	(10)	(13)	(9)	(5)	(37)	(7)	(8)	(4)	(8)	(27)	(7)	(12)	(5)	(3)	(27)
	Pharma	9	8	10	7	34	7	5	12	8	32	4	4	5	6	19
	Total	24	27	26	33	109	32	27	24	17	101	18	29	31	31	108

* Including performance of America/Europe sales subsidiaries

Performance by Business Unit (1)

Green Chemicals – Copolyester & Monomer

4Q24 Performance


Revenue **208bn KRW** (+5.2% YoY, Δ 9.3% QoQ)
Revenue growth due to improvement of the product portfolio and span of application

Operating Profit **30bn KRW** (+66.6% YoY, Δ 5.2% QoQ)
Increase in profit size and improvement in profitability due to the expansion of high-value product sales

1Q25 Outlook


High-Value Portfolio Expansion vs. Changes in Global Dynamics

Revenue




* Including performance of America/Europe copolyester sales subsidiaries


Operating Profit and Margin



Sales Volume Proportion by Application



Sales Volume Proportion by Region



* Data above only refers to Copolyester sales

Performance by Business Unit (2)

Life Science - Pharma

4Q24 Performance

Revenue **106bn KRW** (+0.3% YoY, +25.9% QoQ)

Continuing strong sales
of key products and distribution

Operating Profit **6bn KRW** (Δ 26.0% YoY, +13.0% QoQ)

Profit scale reduction due to cost
increases and price cuts

1Q25 Outlook


Expansion of existing
product sales

vs.

Increase in
marketing costs


Revenue

(Unit: billion KRW)




Operating Profit and Margin

(Unit: billion KRW)



Revenue Proportion



Main Products



Joins

Natural product based
anti-arthritic treatment



Ginexin

blood circulation
disorder treatment &
Cognitive enhancer



Rivastigmine patch

Anti-dementia
treatment patch



Performance by Business Unit (3)

Life Science - SK bioscience

4Q24 Performance

Revenue **157bn KRW** (+73.1% YoY, +154.4% QoQ)
Expansion of scale through the new consolidation of IDT Biologika


Operating Profit **△51bn KRW** (Loss Continued YoY, Loss Continued QoQ)
Deficit expansion due to intensified product competition and expanded investment

1Q25 Outlook

Export of varicella vaccine and expansion of distribution revenue for Sanofi vaccines


Revenue

(Unit: billion KRW)



Operating Profit and Margin

(Unit: billion KRW)



Overview

SKYVAX

- Expanding global reach through partnership
- SKYCellflui
 - Acquired approval in Indonesia ('24.10)
 - Next Generation World-Class Product ('24.11)
- SKYVaricella: New order of 55 bn KRW from PAHO
- SKYZoster: Continuous demand based on price competitiveness and vaccination convenience

Vaccine distribution

- Expanded sales of Sanofi vaccines

IDT Biologika

- Turnaround through operational optimization and revenue expansion
- Strengthening synergy with SKBS

PCV21 (pneumococcal vaccine).

- Completion of the initiation of Phase 3 clinical trials in Australia and planning for the initiation of Phase 3 clinical trials in the U.S., Korea, and Europe in 2025.
- Expansion of the joint development agreement for NextGen PCV

Business Update




Key Application Cases of Recycled Materials

Continuous development of recycled applications and customer expansion through technology collaboration with brand owners.

	Client	Application	Discussion/ Commercialization
CR-Copolyester (ECOTRIA CR)	Woosung Platch	Cosmetic package	Jun 2021
	YONWOO ¹⁾	Cosmetic package	Mar 2023
	COSMAX ¹⁾	Cosmetic package	Apr 2023
	KNK	Toothbrush	Apr 2023
	Estee Lauder ¹⁾	Cosmetic package	Oct 2023
	Pacur	Medical packaging	Feb 2024
	Toly	Cosmetic package	Oct 2024
CR-PET (SKYPET CR)	SAMDASOO	Water bottle	Jan 2022
	ART IMPACT- PROJECT 1907	Fiber	Mar 2023
	Ottugi	Sauce bottle	Jun 2023
	Sonopress	LP	Oct 2023
	Hyosung Advanced Materials / Hankook Tire	Tirecord and Tire	Mar 2024
	Kooksoondang Brewery ¹⁾	Beverage Container	Jul 2024
	Hyundai-KIA	Automotive parts	Dec 2024

Collaboration in the development of eco-friendly automotive materials

- Application of SK Chemicals recycled materials into six components of the eco-friendly vehicle (Kia EV3 study car)
- Completion of quality implementation for commercialization through 14 months of collaboration
- Aiming to achieve a Car-to-Car Closed Loop based on circular recycling technology



1) MOU signed - Ongoing validation and other processes with various brand owners beyond the major cases mentioned above

2) CR-PET and FLEXIA(Soft polyester materials that replace PVC)

New Growth Driver– SKMU Combined Heat and Power Generation (CHP) Plant

Securing competitiveness in the utility business through subsidiary's new power facility expansion,

Business

▪ Business Overview

- Converting to LNG, establishing eco-friendly district energy system
- Stable industrial power and steam supply within the area

▪ CAPEX : Approximately 620 Billion KRW

▪ Expected Benefits

- Eco-friendly energy transition reflecting carbon-neutral policies.
- Strengthening utility business capabilities.


▪ Facility Production Capacity

(Existing) Steam : 490t/h , Electricity : 27MW

(New) Steam : 240t/h , Electricity : 300MW



△ Rendering of the new LNG cogeneration plant



1) 100% ownership as of the

3 Appendix



Financial Statements

Key Financial Information

Governance and Shareholders

Shareholder Returns

Financial Statements (Consolidated)

Balance Sheet

(Unit: billion KRW)

Items	2023	2024
Current assets	2,204	2,385
- Current account	1,828	1,819
- Inventory	377	566
Non-current assets	1,954	2,983
- Investment in affiliated companies and joint ventures	10	10
- Tangible property	1,602	2,459
- Intangible property	54	163
- Other Non-current assets	288	351
Total assets	4,159	5,368
Current liabilities	830	974
Non-current liabilities	653	1360
Total liabilities	1,483	2,334
Equity attributable to the parent company	2,119	2,202
- Capital stock	99	99
- Consolidated capital surplus	1,212	1240
- Consolidated other components of equity	△22	△22
- Accumulated other comprehensive income	△37	22
- Consolidated earned surplus	867	862
Non-controlling interest	557	832
Total equity	2,676	3,034
Total liabilities and equity	4,159	5,368

Income Statement

(Unit: billion KRW)

Items	4Q23	1Q24	2Q24	3Q24	4Q24
Revenue	432	381	414	426	514
- Cost of Revenue	332	296	299	332	412
- Gross profit from Revenue	100	85	115	95	102
- Revenue and administrative expenses	95	97	106	107	131
Operating profits	5	△13	9	-12	-29
- Other non-operating income	2	5	6	1	33
- Other non-operating expense	23	8	7	4	13
- Financial income	21	21	20	23	35
- Financial expense	14	16	20	23	34
- Share of profits	△2	0	△0.4	△0.4	△0.1
Earnings before interest and taxes	△11	△11	8	-16	-9
- Income tax expense	0.1	△3	3	△5	△19
Consolidated net income	△11	△8	5	△11	△11
- Equity attributable to the parent company	△12	△4	9	△4	9
- Non-controlling interest	1	△4	△4	△7	2

Financial Statements (Separate)

Balance Sheet

(Unit: billion KRW)

Items	2023	2024
Current assets	673	812
- Current account	441	559
- Inventory	232	253
Non-current assets	1,283	1,294
- Investment in affiliated companies and joint ventures	444	444
- Tangible property	693	708
- Intangible property	30	31
- Other Non-current assets	115	110
Total assets	1,956	2,106
Current liabilities	653	708
Non-current liabilities	179	236
Total liabilities	832	944
Capital	99	99
Capital surplus	158	158
Other components of equity	△13	△13
Earned surplus	880	917
Total equity	1,124	1,161
Total liabilities and equity	1,956	2,106

Income Statement

(Unit: billion KRW)

Items	4Q23	1Q24	2Q24	3Q24	4Q24
Revenue*	323	317	345	332	347
- Cost of Revenue	254	246	257	251	254
- Gross profit from Revenue	68	71	88	81	92
- Revenue and administrative expenses	52	53	57	52	61
Operating profits*	16	19	31	30	32
- Other non-operating income	17	2	10	0.4	2
- Other non-operating expense	25	7	4	3	10
- Financial income	10	11	12	8	22
- Financial expense	12	12	16	16	22
Earnings before interest and taxes*	7	13	33	19	24
- Income tax expense	△0.1	3	8	4	0.8
Net income	7	9	26	15	23


Key Financial Information (Separate)

(Unit: billion KRW)


Division	2022					2023					2024				
	1Q	2Q	3Q	4Q	Total	1Q	2Q	3Q	4Q	Total	1Q	2Q	3Q	4Q	Total
Cash and Cash Equivalents	106	114	109	119	119	326	222	215	245	245	250	407	341	177	177
Net Debt	129	295	296	317	317	387	412	393	360	360	423	414	397	403	403
CAPEX	15	28	16	25	84	81	24	23	31	159	21	22	16	15	74
Debt Ratio	67.0%	61.8%	64.9%	61.7%	61.7%	82.9%	71.5%	69.9%	74.0%	74.0%	76.4%	90.3%	81.3%	68.2%	68.2%
Current Ratio	141.3%	119.4%	120.3%	120.6%	120.6%	128.9%	133.6%	125.7%	103.1%	103.1%	91.5%	112.0%	114.7%	120.5%	120.5%
EBITDA	40	36	48	39	163	39	34	38	31	141	33	46	44	48	171
EBITDA (%)	13.0%	10.6%	15.6%	12.6%	12.9%	12.6%	10.4%	11.8%	9.4%	11.0%	10.0%	13.2%	13.3%	14.2%	12.6%
ROE	2.1%	1.3%	2.3%	0.5%	-	1.5%	0.4%	1.2%	0.6%	-	0.8%	2.2%	1.3%	1.9%	-

Governance and Shareholders

Governance



Shareholder Composition




Shareholders Category	No. Shares
SK discovery & Affiliated Persons	7,361,072
National Pension	907,747
Foreign Investors	1,943,144
Individuals and Institutions	7,010,963
Treasury Stock	30,857
Total no. of issued shares	17,253,783

*As of end of Q4 2024, Common shares only


Shareholder Returns

Dividend

Payout Ratio



DPS (Common Share)



- 1) The amount includes special dividends, with a dividend of 4,500 KRW per share based on the pre-bonus issue in 2021
 2) Includes interim dividends 400KRW (interim dividends implemented from 2022)

Others

Jun 2017 Retirement of Stock¹⁾

Oct 2021 Announced dividend policy²⁾

Nov 2021 50% capital increase without consideration

Mar 2022 Announced Buy-back of Stock (50 Bn KRW)

Oct 2022 Retirement of Stock (50 Bn KRW)³⁾

- 1) Retired 1,939,120 common shares (7.9% of the total issued shares)
 2) Total dividend amount determined at a payout ratio of approximately 30% (based on separate net income excluding non-recurring gains and losses)
 3) Retired 389,489 common shares

4 Business Introduction


A person in a dark suit stands in a futuristic, dark space. The floor is highly reflective, showing the person's silhouette. In the background, numerous vertical white lines of varying heights create a sense of depth and perspective. A large, thick, green abstract shape, resembling a stylized 'L' or a corner, is positioned in the upper right. Faint, wispy white lines drift through the air, adding to the ethereal atmosphere.

Green Chemicals
Life Science
Global Network


Business Introduction Green Chemicals - Copolyester

Business Introduction

- Functional PETG replaces PC, PMMA, PVC
- Production Process



- Key Products and Applicability



Cosmetics



HHG



HA



Interior
Sheets



Packaging etc.

Core Strategy

- Virgin : Stable profit through high-value goods/portfolio improvement
- Recycle : Establishing entry barriers through market preemption and property standardization

Core Tasks and Strategy

Preempting CR Copolyester Market

- Expanding Recycle sales by cooperating with Global B/O
- Early customer commitments through MOUs, etc.

High-Value Portfolio Expansion


- Targeting High-Value Markets Based on Quality Competency
 - Expanding sales in high-value end-markets (cosmetics/HHG/HA)
 - Leading standardization by securing cosmetics B/O
 - Expanding sales through new applications, replacing other materials
- Expanding Strategic Products/Markets Based on Optimized Facilities
 - Shortening the expansion period of heat-resistant copolyester through early establishment³⁾ of dedicated facilities
 - Accelerating M/S expansion through property enhancement and application expansion

1) R-BHET : Recycled bis-(2-hydroxyethyl) terephthalate 2) CHDM : Cyclohexanedimethanol 3) Investment in Modifying Existing Facilities

Business Introduction Green Chemicals - Recycle


Business Introduction

Production Process



Mechanical Recycling vs. Chemical Recycling Comparison

Choosing Chemical Recycling Method Enables Closed Loop and Sustainability



Core Strategy

- Securing competency as the 1st to commercialize CR-PET in 2023
- Leading the CR-PET market through quality and cost competency

Core Tasks and Strategy

Vertical Integration of Raw Material Supply: Feedstock Innovation

- Internalizing key recycled raw materials (R-BHET) SK Shantou
- Expanding W-PET value chain through extended partnerships

Stabilization of SK Shantou and Advancing of HTR Technology

- Price and quality competitiveness of recycled products and expanding R-BHET production capacity
- Purification process improvement → washing process Normalization → HTR Conversion

Securing Cost Competitiveness at the Level of MR-PET

- Reduction in production costs: Alleviating customer price resistance and promoting market development


Strategic Expansion of CR-PET Sales

- Securing opportunities in the high-value CR-PET market and mass market based on cost competitiveness

Business Introduction **Green Chemicals - Circular**

Business Introduction

- Providing a Closed Loop Solution for Recycling Waste PET Generated During Customers' Production Processes
- Circular Solution



Core Strategy

- Recycling market is expected to form across various industries due to recycling regulations



EEE
WEEE¹⁾

- Obligated to recover and recycle 55-80% of production volume
- Need to establish a closed loop for consumables generated during the process



Automotive
ELV²⁾

- Obligation to use easily disassembled designs and recyclable/reusable materials, with 25% of materials from end-of-life vehicles by 2030
- Need to establish a closed loop for waste obtained from end-of-life vehicles



Fashion
ESPR³⁾

- Obligation for manufacturers to comply with eco-design considering environmental impact and disclose fuel usage during the manufacturing process
- Need to establish a closed loop, prohibiting the disposal of unsold inventory by 2030

... and many other industry needs

1) Waste of Electrical & Electronic Equipment: EU directive on the manufacture/use/disposal of electrical/electronic equipment


2) End of Life Vehicles Regulation: EU regulation on the recycling/reuse of end-of-life vehicles

3) Eco-design for Sustainable Products Regulation: EU regulation for eco-design of sustainable products

Business Introduction **Green Chemicals – Other Business**

BIO Materials

- 100% Eco-Friendly⁴⁾ BIO Material high-Performance Bio-Polyol that Replaces Polyurethane Uses That Are Difficult to Recycle
- Targeting eco-friendly needs by increasing applicability and cost competitiveness




High elastic recovery,
wear resistance,
high flexibility

Lower CO₂ Emissions
Compared to
PTMEG⁵⁾

Commercialized in
February 2022 CAPA:
5,000 Tons/yr

▪ Key Markets and Commercialization Examples



Functional Materials

- Polyester-based adhesives and coatings (BON) and TPEE(PEL)
- Eco-friendly needs in various areas: Increased demand for chemical resistance and conversion to recycled products

▪ Product Introduction and Applicability

SKY BON

SKY PEL

- Polyester-based adhesives and coatings
- Can Coating, Pre-coated metal, Hotmelt, Industrial adhesives, etc.
- TPEE³⁾
- Cable Jacket, Industrial tubes, Duct Mesh Chair Monofilament, etc.



1) PDO : Propanediol 2) PO3G : Poly Oxytrimethylene Glycol 3) TPEE: thermoplastic polyester elastomer 4) Eco-friendly refers to products made from biomass
5) Using Bio-Derived Raw Materials that Reduce Greenhouse Gas Emissions by Approximately 40% Compared to Conventional Petrochemical-Based PTMEG

Business Introduction Life Science - Pharma

Business Introduction

- Competitive product portfolio in botanical and synthetic drug market
- Possesses top-level marketing and partnership capabilities domestically

Main Products

Ginexin-F



ginkgo leaf blood circulation and cognitive function enhancer

Joins



Natural arthritis treatment

Trast



Patch-type arthritis treatment

Mvix S



World's first film-type erectile dysfunction treatment

Rivastigmine Patch



Patch-type dementia treatment

Core Strategy

Continuous business expansion through securing growth drivers based on competency

Mid-term Key Tasks

Strengthening marketing alliance competitiveness

Natural pharmaceutical Product value-up

Expanding Global C(D)MO

Securing R&D growth drivers

Implementation Strategy

Strengthening strategic partnership and operation optimization

Diversifying raw material sourcing and expanding sales

Exploring new Countries for New CMO opportunities


Expanding to new pipelines and accelerating open Innovation



Exploring New Biz Model

Global Network

● HQ(1) ● Domestic Plants(3) ● Overseas Offices (2) ● Overseas Plants (3) ● Overseas Corporations(4)



Ulsan Plant



Certification ISO 14001(Environment) / ISO 45001 (Safety and Health) / ISO 9001(Quality)

Construction Sept 1989 PTA / DMT Plant completion
Jan 2001 CHDM / PETG Plant completion
Feb 2022 PO3G Plant completion

Products Copolyester resin, DMT etc.

Production Capacity 450K tons Annually ^{1) 2)}

Cheongju Plant (S HOUSE)



Certification K GMP/ EU GMP(Solid tablets, patches)

Construction July 2009 Cheongju plant acquisition
July 2012 Production building completion
Mar 2014 Patch building reconstruction

Products Solid tablets and patches

Production Capacity 760 mil. solid tablets, 66 mil. patch pouches annually

SK Shantou



Certification 2019 r-BHET , CR-PET Plant takeover (Shuye)
Mar 2023 Acquisition of Tangible Assets (Shuye)

Construction r-BHET , CR-PET etc.

Production Capacity r-BHET : 70K tons / CR-PET 50K tons Annually

Andong Plant (L HOUSE)



Certification MFDS & EU GMP Certification

Construction Dec 2012 Construction Completed

Products Flu vaccine, varicella/herpes zoster vaccine, COVID vaccine (CMO/CDMO)

Production Capacity Approximately 500 mil. doses annually based on finished products

1) Reflecting operation of new production facility*(#4) from 15th Jun 2021

2) PETG, DMT etc. total capacity